Previous Close | 15.880 |
Open | 15.800 |
Bid | 15.780 x N/A |
Ask | 15.800 x N/A |
Day's Range | 15.700 - 16.060 |
52 Week Range | 12.000 - 26.350 |
Volume | |
Avg. Volume | 4,439,646 |
Market Cap | 93.573B |
Beta (5Y Monthly) | 0.30 |
PE Ratio (TTM) | 30.98 |
EPS (TTM) | 0.510 |
Earnings Date | Mar 30, 2021 |
Forward Dividend & Yield | 0.09 (0.57%) |
Ex-Dividend Date | Jun 16, 2022 |
1y Target Est | 25.73 |
Subscribe to Yahoo Finance Plus to view Fair Value for 3692.HK
Vancouver, British Columbia--(Newsfile Corp. - May 4, 2022) - Kodiak Copper Corp. (TSXV: KDK) (OTCQB: KDKCF) (FSE: 5DD1) (the "Company" or "Kodiak") today reports drill results from the 100% owned MPD copper-gold porphyry project in southern British Columbia. Results from the final seven holes drilled at MPD in 2021 are presented in this release. The fully funded 2022 drill program of up to 25,000 metres is now underway.The Company's first two holes testing the ...
(Bloomberg) -- In a year that’s seen China’s “common prosperity” agenda roil global equity markets, the nation’s policies also created a greater divide between stock winners and losers at home.Most Read from BloombergWHO Downplays Threat of Covid-19 Variant Found in FranceU.S. Logs Record 1 Million Virus Cases With Data DelayOmicron Cases Are Hitting Highs, But New Data Put End in SightHong Kong Scraps Flights, Shuts Bars, Gyms on Omicron ThreatHong Kong Vaccine Surge Sees Majority Pick Sinovac
Keros Therapeutics to receive potential milestone payments up to $170.5 million, $20 million upfront, and tiered royalty payments in the low double digit to high teens on net product sales LEXINGTON, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unm